Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08 |
filingDate |
2002-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf6d82eb177ee676bd27f22621103018 |
publicationDate |
2003-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2003147867-A1 |
titleOfInvention |
Genetically modified cells expressing a TGFbeta inhibitor, the cells being lung cancer cells |
abstract |
The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2862867-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009117566-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011059137-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002192199-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8444964-B2 |
priorityDate |
2000-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |